ValuEngine upgraded shares of Opiant Pharmaceuticals (NASDAQ:OPNT) from a hold rating to a buy rating in a report issued on Thursday, ValuEngine reports.

Other equities research analysts also recently issued research reports about the stock. Northland Securities reiterated a buy rating and issued a $42.00 target price on shares of Opiant Pharmaceuticals in a research report on Friday, May 1st. TheStreet downgraded shares of Opiant Pharmaceuticals from a c- rating to a d+ rating in a research report on Monday, April 6th.

Shares of NASDAQ:OPNT traded up $0.21 during mid-day trading on Thursday, hitting $9.13. The stock had a trading volume of 48,240 shares, compared to its average volume of 166,642. The company has a market cap of $38.89 million, a PE ratio of 4.39 and a beta of 0.78. Opiant Pharmaceuticals has a 12-month low of $8.05 and a 12-month high of $18.23. The company’s 50 day moving average is $10.19 and its 200-day moving average is $11.56.

Opiant Pharmaceuticals (NASDAQ:OPNT) last released its earnings results on Tuesday, May 12th. The technology company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.21). Opiant Pharmaceuticals had a return on equity of 3.27% and a net margin of 29.58%. The company had revenue of $4.28 million during the quarter, compared to analysts’ expectations of $4.63 million. As a group, equities research analysts anticipate that Opiant Pharmaceuticals will post -0.75 EPS for the current fiscal year.

Several institutional investors have recently added to or reduced their stakes in the company. Morgan Stanley lifted its holdings in shares of Opiant Pharmaceuticals by 27.8% during the 1st quarter. Morgan Stanley now owns 4,542 shares of the technology company’s stock worth $44,000 after acquiring an additional 989 shares during the period. Advisor Group Inc. lifted its holdings in Opiant Pharmaceuticals by 43.5% during the 4th quarter. Advisor Group Inc. now owns 6,600 shares of the technology company’s stock valued at $96,000 after purchasing an additional 2,000 shares during the last quarter. Advisor Group Holdings Inc. bought a new position in Opiant Pharmaceuticals during the 1st quarter valued at about $45,000. Acadian Asset Management LLC lifted its holdings in Opiant Pharmaceuticals by 439.7% during the 1st quarter. Acadian Asset Management LLC now owns 8,128 shares of the technology company’s stock valued at $79,000 after purchasing an additional 6,622 shares during the last quarter. Finally, Alambic Investment Management L.P. bought a new position in Opiant Pharmaceuticals during the 1st quarter valued at about $147,000. Institutional investors and hedge funds own 25.27% of the company’s stock.

About Opiant Pharmaceuticals

Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine.

Featured Story: Differences Between Momentum Investing and Long Term Investing

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.